Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-101 Solution 40% in Seborrheic Keratosis
NCT02667236Phase 3Completed
- Sponsor
- Aclaris Therapeutics, Inc.
- Start
- Jan 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in seborrheic keratosis (SK) comparing A-101 Solution with Vehicle Solution (2 arms). Primary endpoint: Proportion of Subjects With Target Lesion Clearance as Assessed by the Physician Lesion Assessment at Day 106. Started Jan 2016; status: completed.
02
Drugs
Eskata
03
Conditions
seborrheic keratosis (SK)
Beyond the preview
Go deeper on NCT02667236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02667236.